Review Timeline | CrossMark Policy | ClinMed Features
logo
International Journal of
Pathology and Clinical Research ISSN: 2469-5807

Citation

Jastania R, Nageeti T (2018) Is p53 Overexpression a Predictor of Worse Outcomes in Endometrioid Endometrial Carcinomas?. Int J Pathol Clin Res 4:081. doi.org/10.23937/2469-5807/1510081

Copyright

© 2018 Jastania R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REVIEW ARTICLE | OPEN ACCESS DOI: 10.23937/2469-5807/1510081

Is p53 Overexpression a Predictor of Worse Outcomes in Endometrioid Endometrial Carcinomas?

Raid Jastania1 and Tahani Nageeti2*

1Assistant Professor, Faculty of Medicine, Umm Al-Qura University, Saudi Arabia

2Consultant Radiation Oncology, Radiation Oncology Department, Jeddah Oncology Centre, King Abdullah Medical City Holy Capital, Saudi Arabia

Abstract

Endometrial cancer (EC) is the most common neoplasm of the female genital tract. Although immunohistochemical methods have been used for detecting several biomarkers for several cancer types, this method is still underutilized in EC. We conducted this review to identify the currently available published evidence to support the utilization of immunohistochemical for p53 protein overexpression as prognostic and predictive biomarkers of disease outcomes in endometrioid endometrial carcinoma.